Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ImmunityBio, Inc.

Get SEC filing alerts via email and in your feed for ImmunityBio, Inc.

IBRX

ImmunityBio, Inc.

About ImmunityBio, Inc.

ImmunityBio is a biotech company developing next-generation immunotherapies that activate the body's immune system to treat cancers and infectious diseases. Its core platforms include cytokine fusion proteins, cell therapies, and vaccine vectors, aimed at creating durable immune memory and overcoming tumor immune evasion. The company focuses on immuno-oncology, including cancer vaccines and therapies that reduce reliance on high-dose chemotherapy, serving global markets with innovative, accessible treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ImmunityBio, Inc.

1
1
ImmunityBio, Inc. ImmunityBio Reports 168% Revenue Growth to $44.2 Million Despite Increased Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ImmunityBio, Inc. ImmunityBio Reports 700% Revenue Growth to $113 Million in 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ImmunityBio, Inc. ImmunityBio Reports 425% Revenue Growth to $32.1 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ImmunityBio, Inc. ImmunityBio Reports Significant Revenue Growth and Operational Developments for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ImmunityBio, Inc. ImmunityBio Reports $16.5 Million Revenue in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ImmunityBio, Inc. ImmunityBio Reports $413.6 Million Net Loss for 2024, Significant Revenue Growth from ANKTIVA

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ImmunityBio, Inc. ImmunityBio Reports $6.1M Revenue in Q3 2024, Net Loss of $85.75M

Via official filing (AI summary) | over 1 year ago | 0 comments